Argenx Stock Surges 41.33% in Trading Volume Ranking 492nd as FDA Approves Efgartigimod

On April 30, 2025, Argenx's trading volume reached 2.05 billion, marking a 41.33% increase from the previous day, ranking 492nd in the day's stock market. Argenx (ARGX) has been on a bullish streak, rising 2.48% and marking its fifth consecutive day of gains, with a total increase of 8.49% over the past five days.

Argenx has announced that its drug efgartigimod has been approved by the FDA for the treatment of generalized myasthenia gravis. This approval is a significant milestone for the company, as it marks the first approval of a drug developed by Argenx. The drug is expected to be launched in the US market in the second half of 2025.

Argenx has also announced that it has entered into a collaboration agreement with a leading biotechnology company to develop a new drug for the treatment of autoimmune diseases. The collaboration will focus on the development of a new antibody therapy that targets a specific protein involved in the pathogenesis of autoimmune diseases. The companies will share the costs and risks of the development program, and will also share the profits from any successful products that result from the collaboration.

Argenx has also announced that it has received a $50 million investment from a leading venture capital firm. The investment will be used to fund the company's ongoing research and development programs, as well as to support the commercialization of its approved drug efgartigimod. The investment is a vote of confidence in Argenx's pipeline and its ability to develop innovative therapies for patients with autoimmune diseases.